ADD/ADHD News

Risk for mania following methylphenidate treatment was significantly lower among individuals with bipolar disorder who received mood stabilizers concomitantly, according to recent findings.

Alcobra Ltd. recently provided an update on the full clinical hold placed by the FDA on the development of new medications for ADHD and Fragile X syndrome.

Lifetime prevalence of ADHD was 9% among adolescents aged 13 to 18 years and past-year prevalence was 4.1% among adults in the U.S., according to the NIMH.

Homework performance significantly improved among children with ADHD who received behavior treatment focused on homework, while typical ADHD medication had no significant effect on homework performance.

The European College of Neuropsychopharmacology Congress, which took place from September 17 to 20 in Vienna, featured presentations, posters, abstracts and addresses on a broad range of topics associated with psychiatry, neurology, psychology, pharmacology and pediatrics.

Alcobra, Ltd. received verbal notice from the FDA’s Division of Psychiatry Products that a full clinical hold was placed on the Investigational New Drug applications for extended-release metadoxine for ADHD and Fragile X syndrome, according to a company press release.

Study findings have indicated that half of all lifetime mental illness begin by age 14 years, according to the NIMH.

Recent findings on suicide in elementary school-aged children suggest a need for common and developmentally-specific suicide prevention strategies for this age group.

College students who screened positively for internet addiction had higher levels of functional impairment, depression and anxiety, attentional problems and ADHD symptoms, according to data presented at the European College of Neuropsychopharmacology Congress.

A 2015 meta-analysis of 175 research studies indicated 7.2% of children aged 18 years and younger worldwide had attention-deficit/hyperactivity disorder.